Bioatla to participate in the citizens jmp life sciences conference

San diego, may 08, 2024 (globe newswire) -- bioatla, inc. (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (cab) antibody therapeutics for the treatment of solid tumors, today announced that the company's management will participate in a fireside chat and one-on-one investor meetings at the citizens jmp life sciences conference, to be held in new york, ny may 13-14, 2024.
BCAB Ratings Summary
BCAB Quant Ranking